Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
08
2021
accepted:
27
04
2022
entrez:
11
5
2022
pubmed:
12
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Endothelin-1 (ET-1) is a potent vasoconstrictor which seems to be involved in the pathogenesis of diabetic retinopathy (DR). However, studies on intraocular ET-1 in DR have been limited. Thus, we investigated aqueous ET-1 levels in patients with DR. A total 85 subjects were included in this prospective study. Those were classified into three groups: advanced DR group included those with severe nonproliferative DR or proliferative DR, whereas early DR group included those with mild nonproliferative DR or moderative nonproliferative DR. Those who underwent cataract surgery and had no concomitant ocular disease were included in the control group. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month for the DR patients, and at the time of cataract surgery for the control group. Advanced DR group included 40 eyes (47.1%), whereas early DR group did 19 eyes (22.4%), and control group (26 eyes, 30.5%). Mean aqueous ET-1 level was 10.1±4.1 pg/mL (6.0-21.0 pg/mL) in advanced DR group, 1.9±0.7 pg/mL (0.6-2.8 pg/mL) in early DR group, and 2.1±1.0 pg/mL (0.7-3.9 pg/mL) in control group (P < 0.001). Advanced DR group was further subdivided into severe nonproliferative DR (15 eyes, 12.8%) and proliferative DR (25 eyes, 34.3%). Mean aqueous ET-1 level was 10.1±4.3 pg/mL (6.0-20.1 pg/mL) in patients with severe nonproliferative DR, and 10.0±4.0 pg/mL (6.0-21.0 pg/mL) in those with proliferative DR (P = 0.928) at baseline. Mean ET-1 level at 1 month after intravitreal injection was 2.5±1.0 pg/mL (0.3-4.8 pg/mL) in patients with severe proliferative DR and 2.9±1.7 pg/mL (1.0-7.0 pg/mL) in those with proliferative DR (P = 0.443). Mean aqueous ET-1 level was significantly reduced in both groups (P < 0.001, respectively). The mean aqueous ET-1 level was significantly higher in the eyes with advanced DR than those with early DR and the control group. The mean aqueous ET-1 level was significantly reduced after intravitreal injections in the advanced DR group. Based on our results, future studies on the exact role of ET-1 in the pathogenesis of DR and future implication for intervention would be helpful for managing DR.
Identifiants
pubmed: 35544533
doi: 10.1371/journal.pone.0268353
pii: PONE-D-21-28261
pmc: PMC9094525
doi:
Substances chimiques
Endothelin-1
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0268353Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S455-8
pubmed: 15838347
Biochem Biophys Res Commun. 2004 Jun 4;318(3):642-8
pubmed: 15144886
Mol Vis. 2010 Jul 10;16:1272-9
pubmed: 20664700
Surv Ophthalmol. 2007 Nov;52 Suppl 2:S115-21
pubmed: 17998035
Diabetologia. 1999 Oct;42(10):1228-34
pubmed: 10525664
J Cardiovasc Pharmacol. 1998;31 Suppl 1:S378-9
pubmed: 9595488
Arch Ophthalmol. 1984 Apr;102(4):527-32
pubmed: 6367725
Am J Ophthalmol. 1994 Jan 15;117(1):72-80
pubmed: 8291596
Exp Diabetes Res. 2007;2007:31867
pubmed: 18288248
Diabetes. 1963 Jul-Aug;12:293-300
pubmed: 14081839
Arch Ophthalmol. 1961 Sep;66:366-78
pubmed: 13694291
Invest Ophthalmol Vis Sci. 1995 Mar;36(3):596-607
pubmed: 7890491
Diabetes Res Clin Pract. 2013 Dec;102(3):218-24
pubmed: 24268633
Int J Ophthalmol. 2010;3(1):19-22
pubmed: 22553510
PLoS One. 2021 Jun 2;16(6):e0252530
pubmed: 34077461
Ophthalmology. 2003 Sep;110(9):1677-82
pubmed: 13129861
Hypertension. 1998 Jul;32(1):89-95
pubmed: 9674643
Curr Eye Res. 1998 Mar;17(3):301-7
pubmed: 9543639
Br J Ophthalmol. 2012 Feb;96(2):151-5
pubmed: 21775765
Retina. 2007 Feb;27(2):222-35
pubmed: 17290206
Graefes Arch Clin Exp Ophthalmol. 1997 May;235(5):283-7
pubmed: 9176676
Eye (Lond). 2008 Feb;22(2):223-8
pubmed: 17001327
J Korean Med Sci. 2014 Dec;29(12):1699-705
pubmed: 25469073
Eur J Pharmacol. 2005 Jul 11;517(3):232-9
pubmed: 15975571
Invest Ophthalmol Vis Sci. 2013 Oct 17;54(10):6827-33
pubmed: 24065813
Ophthalmology. 2004 Aug;111(8):1489-94
pubmed: 15288976
Invest Ophthalmol Vis Sci. 1997 Sep;38(10):2144-51
pubmed: 9331278
Diabetes. 1992 Dec;41(12):1533-9
pubmed: 1446793
Diabet Med. 2015 May;32(5):686-91
pubmed: 25407692
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):272-7
pubmed: 16384973